



Case #PC31283 (S03376)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
Feeley et al

SERIAL NO.: 09/941,206

FILED: 08/28/2001

GROUP ART UNIT: 1617

EXAMINER: J. Kim

DATE: August 18, 2005

TITLE: USE OF AN ALDOSTERONE RECEPTOR ANTAGONIST TO IMPROVE COGNITIVE FUNCTION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.98

Commissioner for Patents
Alexandria, VA 22313

Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement, supplements the Information Disclosure Statement being filed herewith simultaneously. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 19-1025.

This newly cited document is as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

Christopher W. Slavinsky
Attorney for Applicants
Registration No. 54,456
Tel: 314-274-7008

Pharmacia Corporation
Of Pfizer Inc
Corporate Patent Department
P.O. Box 1027
Chesterfield, MO 63306



Sheet 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.:PC31283(3376)	APPLICATION NO.: 09/941,206
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		INVENTOR: Fedde, et al.
(Use several sheets if necessary)		Filed: 8/28/2001
		Group: 1617

U.S. PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	2	Fogari et al, Drugs Aging, 21 (6), 377-393, 2004
	3	Croom et al, Am J Cardiovasc Drugs, 5(1), 51-69, 2005
	4	Rychlik et al, Expert Rev Pharmacoeconomics Outcomes Res, 5(3), 277-286,2005
	5	Hobbs et al, American Journal of Therapeutics, 11, 467-472, 2004
	6	Sosin et al, Current Pharmaceutical Design, 10, 3569-3577, 2004
	7	Mehjert et al, Heart, 90, 1010-1015, 2004
	8	Akosah et al, Dis Manage Health Outcomes, 12(4), 221-227, 2004

EXAMINER	DATE CONSIDERED
----------	-----------------